Agilon health’s third quarter results received a positive market response, propelled by notable gains in operational efficiency and clinical program performance. Management pointed to improved identification and treatment of complex conditions such as heart failure, as well as enhanced support for primary care partners, as key contributors. CEO Tim O’Rourke highlighted technology-enabled clinical pathways and investments in data infrastructure as central to reducing unnecessary medical costs and improving patient outcomes.
Is now the time to buy AGL? Find out in our full research report (it’s free for active Edge members).
agilon health (AGL) Q3 2026 highlights:
- Revenue $1.52 billion vs S&P analysts’ estimates of $1.46 billion (5.9% year-on-year growth, 4.2% beat)
- Adjusted EPS $2.08 vs S&P analysts’ estimates of -$0.73 (significant beat)
- Adjusted EBITDA $63.68 million vs analyst estimates of $686,860 (4.2% margin, significant beat)
- Revenue guidance The company lifted its revenue guidance for the full year to $5.88 billion at the midpoint from $5.82 billion, a 1.1% increase
- EBITDA guidance $150 million at the midpoint for the full year, above analyst estimates of $86.41 million
- Operating margin 1.6%, up from -9.1% in the same quarter last year
- Customers 566,000, up from 549,000 in the previous quarter
- Market capitalization $1.91 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from agilon health’s Q3 earnings call
- Eduardo Ron (Truist Securities): asked about the timeline for new market growth and whether new contracts signed in 2027 would impact results in 2028 or 2029. CEO Tim O’Rourke clarified that most new partnerships signed in 2027 would begin contributing in 2028, given the typical 12-18 month onboarding period.
- Ryan Langston (TD Cowen): inquired about the preference for risk-sharing arrangements versus care coordination fees in new markets. O’Rourke responded that agilon is focused on risk-based contracts rather than interim care coordination models, highlighting increased confidence in their underwriting.
- Tiffany Yuan (Barclays): questioned how agilon participates in payer bonus revenue as STARS ratings recover. CFO Jeff Schwaneke confirmed that agilon is compensated for its contributions as bonus revenue improves, participating in both downside protection and upside opportunities.
- Jack Slevin (Jefferies): asked about the drivers behind improved revenue and cost trends. Schwaneke attributed outperformance to successful clinical pathways and favorable claims development, with higher risk adjustment revenue and lower-than-expected medical cost trends driving results.
- Matthew Mardula (William Blair): sought updates on the enhanced data pipeline and the path to full coverage. Schwaneke indicated that data integration now covers the mid-80% range, with incremental gains becoming more labor-intensive, but long-term goals target the low to mid-90% range.
Catalysts in upcoming quarters
Looking ahead, our analysts will closely monitor (1) the pace of ACO membership growth and successful onboarding of new physician partners, (2) further rollout and adoption of technology-enabled clinical pathways for chronic conditions, and (3) evidence that payer contracting continues to drive margin improvement without sacrificing growth. Progress in integrating data systems and expanding quality initiatives will also be key indicators of sustained performance.
agilon health currently trades at $112.50, up from $96.23 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).
Our favorite stocks right now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
